Evidence map›Paper›PMID 37324017›Full record

ArticleFrontiers in oncology2023

Clinical utility of geriatric assessment tools in older patients with gastrointestinal cancer.

Ayako Doi, Takuro Mizukami, Hiroyuki Takeda, Kumiko Umemoto, Hiroyuki Arai, Yoshiki Horie, Naoki Izawa, Takashi Ogura, Yu Sunakawa

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ayako DoiSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Takuro MizukamiSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Hiroyuki TakedaSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Kumiko UmemotoSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Hiroyuki AraiSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Yoshiki HorieSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Naoki IzawaSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Takashi OguraSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
Yu SunakawaSt. Marianna University School of Medicine, Department of Clinical Oncology, Kawasaki, Japan.
St. Marianna University School of Medicine · JPKawasaki Municipal Hospital · JPNTT (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Geriatric 8 (G8) and instrumental activities of daily living (IADL) are recommended to predict overall survival (OS) or risk of serious adverse events (SAEs) in older cancer patients. However, the clinical utility is relatively unknown in older patients suffering malnutrition with gastrointestinal (GI) cancer, including gastric cancer (GC) and pancreatic cancer (PC). Materials and methods: We retrospectively included patients aged ≥65 years with GC, PC, and colorectal cancer (CRC) who received a G8 questionnaire at first visit from April 2018 to March 2020. The associations between G8/IADL and safety or OS were assessed in patients with advanced/unresectable tumors. Results: Of 207 patients (median age: 75 years), the median G8 score was 10.5 and normal G8 score rate was 6.8%. Both the median G8 score and normal G8 (>14) score rate numerically increased in the order of GC < PC < CRC. There was no clear association between the G8 standard cutoff value of 14 and SAEs or OS. However, OS was significantly longer in patients with G8 >11 than in those with G8 ≤11 (19.3 vs. 10.5 months, Conclusion: The G8 cutoff value of 14 would not be clinically useful in patients with GI cancer for predicting OS or SAEs; however, the cutoff value of 11 and IADL may be useful to predict OS for older patients with GI cancers including GC and PC.

Indexed as

chemotherapyelderlygastrointestinal cancer (GI cancer)geriatric 8 (G8)instrumental activities of daily living (IADL)

Identifiers

PMID37324017
PMCPMC10264801
OpenAlexW4378904672

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.